9-Oxabicyclo[3.3.1]nonan-2-ol, 5-methoxy-, endo-

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 9-Oxabicyclo[3.3.1]nonan-2-ol, 5-methoxy-, endo-
• 英文别名: 5-methoxy-9-oxabicyclo[3.3.1]nonan-2-ol
• 化学式: C₉H₁₆O₃
• 分子量: 172.22
• InChiKey: TUXDWEMXWQWLKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Topical antiviral formulations and methods of using the same
  申请人：McElvany Christopher A.

  公开号：US10456435B2

  公开（公告）日：2019-10-29

  Antiviral pharmaceutical compositions comprising one or more cannabinoid compounds in the form of lip-balms, creams and ointments. A specific embodiment provides a topical composition formulated as a lip-balm.

  包含一种或多种大麻素化合物的唇膏、膏霜和软膏形式的抗病毒药物组合物。一个具体的实施方案提供了一种配制成唇膏的局部组合物。
• Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
  申请人：Stephenson T. Diane

  公开号：US20060160776A1

  公开（公告）日：2006-07-20

  The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a cannabinoid agent in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了用于治疗受试者中枢神经系统损伤的组合物和方法。更具体地说，本发明提供了一种用于治疗中枢神经系统缺血性疾病或中枢神经系统创伤性损伤的组合疗法，包括向受试者施用大麻素制剂与环氧合酶-2 选择性抑制剂。
• Oleaginous pharmaceutical and cosmetic foam
  申请人：Tamarkin Dov

  公开号：US20070292461A1

  公开（公告）日：2007-12-20

  The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition.
• SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT
  申请人：TAMARKIN Dov

  公开号：US20080292560A1

  公开（公告）日：2008-11-27

  A carrier, composition or foam formulation comprising; a silicone; about 25% to about 98% of a solvent selected from the group consisting of (1) a propylene glycol or derivative and (2) a polyethylene glycol (PEG) or derivative or mixtures thereof; 0% to about 48% of at least one secondary solvent; and an Accommodating Agent or Complex; and methods of treatment. A hygroscopic silicone in glycol containing composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and a therapeutic agent.
• HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES
  申请人：Tamarkin Dov

  公开号：US20080299220A1

  公开（公告）日：2008-12-04

  A waterless composition suitable for delivery of an active agent to a body surface or cavity includes a vehicle having about 70% to about 99% by weight of a hydrophilic polar solvent, said hydrophilic solvent selected from the group consisting of (i) a mixture of two or more different polyethylene glycols (PEGs), wherein at least one PEG is a high molecular weight PEG having a melting point greater than 25° C.; and (ii) propylene glycol (PG); about 0% to about 10% of at least one surface active agent; about 0% to about 5% of a polymeric agent; about 0% to about 30% of a secondary hydrophilic solvent; and about 0% to about 5% of a silicone oil; and about 3% to about 25% hydrophobic propellant. The composition is otherwise substantially free of a hydrophobic solvent and includes at least one of a surface active agent and a polymeric agent. The vehicle and the propellant are sufficiently miscible that the components may be homogeneously distributed with mild shaking.